Results 171 to 180 of about 2,479 (207)

Erenumab/fremanezumab/galcanezumab

Reactions Weekly, 2021
openaire   +2 more sources

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Headache, 2021
Richard B Lipton, Dawn C Buse
exaly  

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

Headache, 2021
Fumihiko Sakai, Norihiro Suzuki, Byung Kun Kim   +2 more
exaly  

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

Headache, 2021
Fumihiko Sakai, Norihiro Suzuki, Byung Kun Kim   +2 more
exaly  

Erenumab/fremanezumab/galcanezumab

Reactions Weekly, 2023
openaire   +1 more source

Fremanezumab zugelassen

DNP - Der Neurologe & Psychiater, 2019
openaire   +2 more sources

Wirtschaftliche Verordnung von Fremanezumab

DNP - Der Neurologe & Psychiater, 2021
openaire   +1 more source

Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry

European Journal of Neurology, 2023
Georgia Xiromerisiou
exaly  

Wirksame Migräneprophylaxe mit Fremanezumab

DNP – Die Neurologie & Psychiatrie, 2022
openaire   +1 more source

Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach

Cephalalgia, 2021
Aksana Kaefer Jones
exaly